China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products (ATMPs), has announced the completion of its Pre-Series D financing round, raising close to RMB 200 million (USD 27.4 million). This funding round comes on the heels of the Series C+ financing round completed in April last year and was supported by prominent investors, including the Beijing Changping Industrial Development Investment Fund and the Beijing Medical and Health Industry Investment Fund, a government-guided fund with assets worth RMB 20 billion (USD 2.74 billion).
uBriGene’s Background and Growth Strategy
Founded in 2015, uBriGene has emerged as a key player in the ATMPs CDMO space. The company plans to channel the proceeds from this financing round into several strategic areas. These include the acceleration of its ATMPs CDMO commercial manufacturing base construction, the iteration of its technologies, and the expansion of its global CDMO services footprint.
Enhancing Global CDMO Services
The investment will play a crucial role in enhancing uBriGene’s capabilities, allowing the company to better serve the growing demand for advanced therapy medicinal products. By focusing on the construction of a robust manufacturing base and the continuous iteration of its technologies, uBriGene is poised to become a leading global CDMO in the ATMP sector.-Fineline Info & Tech
